ZA200104803B - Treatment of infertility. - Google Patents
Treatment of infertility. Download PDFInfo
- Publication number
- ZA200104803B ZA200104803B ZA200104803A ZA200104803A ZA200104803B ZA 200104803 B ZA200104803 B ZA 200104803B ZA 200104803 A ZA200104803 A ZA 200104803A ZA 200104803 A ZA200104803 A ZA 200104803A ZA 200104803 B ZA200104803 B ZA 200104803B
- Authority
- ZA
- South Africa
- Prior art keywords
- hormone
- agonist
- mas
- oocytes
- days
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 17
- 208000000509 infertility Diseases 0.000 title claims description 8
- 230000036512 infertility Effects 0.000 title claims description 7
- 231100000535 infertility Toxicity 0.000 title claims description 7
- 210000000287 oocyte Anatomy 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 42
- 230000035800 maturation Effects 0.000 claims description 26
- 239000000556 agonist Substances 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 22
- 239000005557 antagonist Substances 0.000 claims description 22
- 235000013601 eggs Nutrition 0.000 claims description 16
- 229940088597 hormone Drugs 0.000 claims description 16
- 239000005556 hormone Substances 0.000 claims description 16
- 239000000960 hypophysis hormone Substances 0.000 claims description 16
- 239000000601 hypothalamic hormone Substances 0.000 claims description 16
- 229940043650 hypothalamic hormone Drugs 0.000 claims description 16
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 14
- 238000003744 In vitro fertilisation Methods 0.000 claims description 11
- 210000001161 mammalian embryo Anatomy 0.000 claims description 7
- 210000001136 chorion Anatomy 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 230000035558 fertility Effects 0.000 claims description 3
- 230000001592 luteinising effect Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000027758 ovulation cycle Effects 0.000 claims description 2
- 230000001360 synchronised effect Effects 0.000 claims description 2
- 239000002609 medium Substances 0.000 description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 11
- 108010086677 Gonadotropins Proteins 0.000 description 8
- 102000006771 Gonadotropins Human genes 0.000 description 8
- 239000002622 gonadotropin Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000021121 meiosis Effects 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- -1 e.g. Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010023204 Joint dislocation Diseases 0.000 description 2
- 108010057021 Menotropins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 108010021717 Nafarelin Proteins 0.000 description 2
- 108010020661 Profasi Proteins 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 108010006578 follitropin alfa Proteins 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000002474 gonadorelin antagonist Substances 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 229940057854 gonal f Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940086546 synarel Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940064298 pregnyl Drugs 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Description
TREATMENT OF INFERTILITY
This invention relates to an improved method of in vitro fertilisation (hereinafter des- ignated IVF).
Since the first IVF pregnancy was delivered in 1978, this procedure has resulted in thousands of pregnancies and opened a vast new frontier of research and treatment for the infertile couples. Still, there is a significant need for improved infertility treat- ment modalities today. It is presumed that about one out of seven couples experi- ence problems with subfertility or infertility.
IVF of human oocytes has become commonly used for the treatment of female and male subfertility. The standard IVF treatment includes a long phase of hormone stimulation of the female patient, e.g. 30 days, which is initiated by suppressing the patient's own follicle stimulating hormone (hereinafter designated FSH) and luteinis- ing hormone (hereinafter designated LH) by gonadotropin releasing hormone (here- inafter designated GnRH), and this is followed by injections of exogenous gonad- otropins, e.g. FSH and/or LH, in order to ensure development of multiple preovula- tory follicles and aspiration of multiple in vivo matured oocytes immediately before ovulation. The aspirated oocyte is subsequently fertilised in vitro and cultured, typi- cally for three days before transferral back into the uterus at the 4-8 cell stage. Con- tinuous efforts have been made to optimise and simplify this procedure. Neverthe- less, the overall pregnancy rate cannot be increased significantly over about 20% with the current treatment modalities. In a large European survey of IVF patients, it was found that 7.2 oocytes out of 11.5 aspirated oocytes per patient had undergone resumption of meiosis immediately before fertilisation, only 4.3 oocytes were fertil- ised and only 2.2 oocytes reached the 8-cell embryo stage after fertilisation and in vitro culture (ESHRE, Edinburgh, 1997).
SUBSTITUTE SHEET (RULE 26)
Due to the very unpredictable quality of the state of the art embryos today, more than one embryo has to be transferred just to give a reasonable chance of success.
Therefore, it is common to transfer 2-3 embryos (up to 5 embryos in some countries), which carries the very large side effect of multiple pregnancies with great discomfort and risk to both patient and children. Moreover, it has been estimated that the in- creased health care expenses due to multiple birth (twins, triplets etc.) is exceeding the entire IVF expenses.
Hence, there are several disadvantages with the current treatment, the four most no- table being: 1. the risk of ovarian hyperstimulation with injecting gonadotropins which is a poten- tial fatal condition that requires hospitalisation, 2. multiple pregnancies (50-1.000 times the normal frequency of twins and triplets, respectively), 3. the existence of considerable patient segments that do not tolerate the current method due to, e.g. polycystic ovarian syndrome and many diabetics, 4. a potential long-term cancer risk.
Furthermore, weight gain, bloating, nausea, vomiting, labile mood and other patient discomforts together with patient reluctance to inject themselves are reported as disadvantages.
It is known from WO 96/00235 that certain sterol derivatives can be used for regulat- ing meiosis. An example of such a sterol is 4,4-dimethyl-5a-cholesta-8,14,24-triene- 3p-ol (hereinafter designated FF-MAS).
Herein, the term MAS compounds designates compounds which mediate the meiosis of oocytes. More specifically, MAS compounds are compounds which in the test de- scribed in Example 1 below has a percentage germinal vesicle breakdown (hereinaf- ter designated GVB) which is significantly higher than the control. Preferred MAS compounds are such having a percentage GVB of at least 50%, preferably at least 80%.
SUBSTITUTE SHEET (RULE 26)
» R 3 .
Examples of MAS compounds are mentioned in WO 96/00235, 96/27658, 97/00884, 08/28323, 98/54965 and 98/55498, more specifically in Claim 1 thereof.
In WO 95/000265, some potential meiosis regulating substances were tested on im- mature female mice. 48 hours before the test animal were killed by cervical disloca- tion, they were given a single injection of human menopausal gonadotropin contain- ing 20 IU FSH and 20 IU LH. The ovaries were removed, placed in a hypoxanthine medium and freed of extraneous tissue. Then, the oocytes were punctured out of the follicles, freed from cumulus cells and cultured in a medium containing a meiosis regulating derivative.
At present, in vitro maturation in humans has proven highly unsuccessful despite substantial interest and clinical efforts.
One object of the present invention is to treat human infertility.
Another object of the present invention is to improve the maturation of hu- man oocytes.
Another object of the present invention is to improve the synchrony of nu- . 20 clear, cytoplasmic and/or membranous oocyte maturation.
Another object of the present invention is to improve the fertility of oocytes.
Another object of the present invention is to improve the rate of implantation of oocytes by human in vitro maturation and fertilisation.
Another object of the present invention is to diminish the incidence of human preembryos with chromosome abnormalities (aneuploidy).
Another object of the present invention is to improve the cleavage rate of human preembryos.
Another object of the present invention is to improve the quality of human preembryos. :
SUBSTITUTE SHEET (RULE 26)
4 te
It has now, surprisingly, been found that the IVF can be improved substantially when a MAS compound is added at the stage in the usual method of performing in vitro fertilisation where one would expect that the maturation had taken place in vivo.
Briefly, the present invention relates to a method for human in vitro fertilisation wherein a woman, within a consecutive period of 30 days, is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively final matured or the oocyte maturation is synchronised in vitro in contact with a MAS compound.
Preferred embodiments of this invention are those stated in the sub claims below.
] Referring to the female cycle, on way of performing the treatment of this invention is as follows:
Around day 21 in one cycle to around day 15 in the following cycle: The eggs are stimulated by treating the woman with GnRH, e.g. Synarel (400-600 ug per day).
Around days 6-15 in the second cycle: The eggs are stimulated by treating the woman with FSH, e.g. Gonal-F, Puregon or Humegon (150-400 IU per day).
Around days 15-16 in the second cycle: The eggs are stimulated by treating the woman with hCG, e.g. Pregnyl or Profasi (2000-5000 IU per day).
Around day 18 in the second cycle: The eggs are retrieved from the woman.
Around day 18-19 in the second cycle: The eggs are maturated with a MAS com- pound in order to stimulate the meiosis. In this additional maturation step, the con- ~ SUBSTITUTE SHEET (RULE 26)
centration of MAS compound may be in the range about 0.1-100 umol per litre, e.g. 10-20 umol per litre. The time for this maturation step may be in the range around 1- 60 hours. If the preovulatory follicles are induced to luthenise with a lutenising hor- mone or an agonist or antagonist thereof or an active derivative thereof and/or hu- man chorion gonadotropins or an agonist or antagonist thereof or an active derivative thereof, the maturation of the oocytes with the MAS compound is for a duration of about 1-15 hours, preferably about 6 hours. If, however, preovulatory follicles are not induced to lutenise with a lutenising hormone or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropins or an agonist or an- tagonist thereof or an active derivative thereof, the maturation of the oocytes with the
MAS compound is for duration of about 15-60 hours.
Around days 19-21 in the second cycle: The eggs are fertilised in vitro.
From the day before aspiration, the woman will receive an oestrogen, e.g., oestrogen valerate (2 x 10 mg daily). Two days later, she will also receive a progestogen, e.g.,
Progestane vagetoria, daily, which will render the lining of the uterus more prone to receive the future embryos. The duration of this treatment will be individually de- signed per patient. The doctor can chose among a variety of oestrogens and pro- gestogens.
Around day 21 in the second cycle: One or more embryos are transferred to the woman's uterus.
The description above is designated MAS add-on to the existing IVF protocol to im- prove efficacy by mediating a final or complete maturation or synchrony in the oo- cyte. Alternatively, MAS can be used to rescue oocytes in cycles that otherwise would be cancelled due to apparent FSH hyper response. In this instance, the re- sponsible clinician would consider cancellation based on the estradiol profile, ultra- sonography (PCO like response) thus avoiding the hCG treatment. The oocytes are aspirated at the time around day 15-16 substituting hCG treatment.
SUBSTITUTE SHEET (RULE 26)
Apart from the additional maturation step with a MAS compound, the above IVF is performed the usual way. Since one expects that by the traditional IVF procedure the eggs had been matured sufficiently, one would not expect that it would have any ad- ditional effect to add this additional maturation step. i
Most of the steps in the above treatment and procedure are performed in a known manner and the remaining steps are performed in a manner known per se. More de- tails about the removal of the oocytes from follicles in the ovary, culturing of the iso- lated oocytes, the culture medium to be used, the fertilisation with sperm, and the transfer of the embryo to the fallopian tube can be found in the literature, for exam- ple, in US patent specification No. 5,693,534 which is hereby incorporated by refer- ence.
According to this invention, the MAS compound is added to the culture medium used. In this medium, the amount of the MAS compound is in the range from about 0.01 to about 100 uM, preferably in the range from about 0.1 to about 100 uM.
A preferred reason for treating a woman, within a consecutive period of 30 days, with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative is to obtain multiple preovulatory follicles.
Hypothalamic hormones are hormones present in the human hypothalamus. Pituitary hormones are hormones present in the human pituitary gland. Gonadotropic hor- mones are hormones secreted by the anterior lobe of the pituitary in vertebras and by mammalian placenta, which control the activity of gonads. Chemically, they are glycoproteins. Examples of gonadotropic hormones are FSH, LH and chorion go- nadotropin, e.g. human chorion gonadotropin (hereinafter designated hCG). FSH stimulates growth of ovarian follicles and their oocytes in ovary and the formation of spermatozoa in testis. FSH can, e.g., be menopausal FSH or recombinant FSH. In females, LH activates the oestrogen-producing tissue of the ovaries to produce pro- gesterone, probably promotes the final stages of the development of ovarian follicles, initiates the final oocyte maturation, induces ovulation and in mammals initiates cor-
SUBSTITUTE SHEET (RULE 26)
. pus luteum development. These hormones are known. It is obvious for the skilled art worker that, alternatively, agonists or antagonists of these hormones can be used. It is also obvious for the skilled art worker that, alternatively, active analogues of these hormones can be used. Some of these agonists, antagonists and analogues are known and other can be prepared by process known per se. Exampies of such known processes are chemical synthesis and genetic engineering.
In a preferred embodiment, the present invention relates to a method or use wherein the consecutive period of 30 days within which the woman is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is at least about 7 days, preferably at least about 10 days, more preferred at least about 14 days.
In another preferred embodiment, the present invention relates to a method or use ) 15 wherein the woman is treated for infertility, and/or for improving the maturation of her oocytes, and/or for improving the synchrony of nuclear, cytoplasmic and/or membra- nous oocyte maturation, and/or for improving the fertility of her oocytes, and/or for improving the rate of implantation by human in vitro maturation and fertilisation : 20 In another preferred embodiment, the present invention relates to a method or use wherein the consecutive period is one menstrual cycle.
In another preferred embodiment, the present invention relates to a method or use wherein the maturation of the oocytes with the MAS compound is for a duration of about 15 to about 60 hours. in another preferred embodiment, the present invention relates to a method or use wherein preovulatory follicles are induced to lutenise with a luteinising hormone (LH) or an agonist or antagonist thereof or an active derivative thereof and/or human chorion gonadotropin (HCG) or an agonist or antagonist thereof or an active deriva- tive thereof.
SUBSTITUTE SHEET (RULE 26)
8 oo
In another preferred embodiment, the present invention relates to a method or use } wherein the maturation of the oocytes with the MAS compound is for a duration of about 1 to about 15 hours, preferably about 6 hours.
In another preferred embodiment, the present invention relates to a method or use wherein the dosage of MAS compound used is about 0.01 to about 100 umol per li- tre, preferably about 0.1 to about 100 pmol per litre.
In another preferred embodiment, the present invention relates to a method or use wherein the MAS compound is one of the compounds mentioned in WO 96/00235, 96/27658, 97/00884, 98/28323, 98/54965 and 98/55498, more specifically com- pounds mentioned in Claim 1 thereof.
In another preferred embodiment, the present invention relates to a method or use wherein the MAS compound is FF-MAS.
Additionally, the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof in the manufacture of a hormone product which is to be administered to a woman who, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof, and from whom, immediately after said period, one or more oo- cytes are aspirated, where after said oocyte(s) is/are cultivated in a convenient me- dium containing a MAS compound as defined herein, where after said oocyte(s) is/are fertilised with human sperm, and where after the resulting embryo(s) is/are transferred to a woman.
Additionally, the present invention relates to the use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof and of a MAS compound for the manufacture of a medicament for the treat- ment of human in vitro fertilisation wherein a hypothalamic hormone and/or a pitui- tary hormone or an agonist or antagonist thereof or an active derivative thereof is,
SUBSTITUTE SHEET (RULE 26)
wo — - PCT/DKO00/00074 : within a consecutive period of 30 days, used to treat a women and, thereafter, the
MAS compound is used in an in vitro oocyte maturation of the egg or eggs retrieved from this woman.
Additionally, the present invention relates to a pharmaceutically kit in unit dosage form for use by in vitro fertilisation comprising separate unit dosages, said kit com- prising separate dosage units for sequential daily administration of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for sequential daily administration and 1 dosage units of a MAS compound. This kit may have the preferred features described above.
The present invention is further illustrated by the following examples, which, how- ever, are not to be construed as limiting. The features disclosed in the foregoing de- scription, in the following examples and in the claims may, both separately and in any combination thereof be material for realising the invention in diverse forms thereof.
Example 1 : 20
Method used for electing MAS compounds
Oocytes were obtained from immature female mice (C57BL/6J x DBA/2J F1, Bom- holtgaard, Denmark) weighing 13-16 grams, that were kept under controlled tem- perature (20-22°C), light (lights on 06.00-18.00) and relative humidity (50-70%). The mice received an intra-peritoneal injection of 0.2 ml gonadotropins (Gonal-F, Serono) containing 20 IU FSH and 48 hours later the animals were killed by cervical disloca- tion. The ovaries were dissected out and the oocytes were isolated in Hx-medium (see below) under a stereomicroscope by manual rupture of the follicles using a pair of 27 gauge needles. Spherical oocytes displaying an intact germinal vesicle (here- inafter designated GV) were divided in cumulus enclosed oocytes (hereinafter desig- nated CEQ) and naked oocytes (hereinafter designated NO) and placed in a-
SUBSTITUTE SHEET (RULE 26)
minimum essential medium (a-MEM without ribonucleosides, Gibco BRL, Cat. No. 22561) supplemented with 3 mg/ml bovine serum albumin (BSA, Sigma Cat. No. A- 7030), 5 mg/ml human serum albumin (HSA, Statens Seruminstitut, Denmark), 0.23mM pyruvate (Sigma, Cat. No S-8636), 2 mM glutamine (Flow Cat. No. 16-801), 100 IU/ml penicillin and 100 ng/ml streptomycin (Flow, Cat No. 16-700). This medium was supplemented with 3 mM hypoxanthine (Sigma Cat. No. H-9377) and desig- nated Hx-medium.
The oocytes were rinsed three times in Hx-medium and oocytes of uniform size were divided into groups of CEO and NO. CEO and NO were cultured in 4-well muiltidishes (Nunclon, Denmark) in which each well contained 0.4 ml of Hx-medium and the compound to be tested in a concentration of 10 pM. One control well (i.e., 35-45 oocytes cultured in identical medium with no addition of test compound) was always cultured simultaneously with 3 test wells (35-45 oocytes per well supple- mented with test compound).
The oocytes were cultured in a humidified atmosphere of 5% CO, in air for 24 hours at 37°C. By the end of the culture period, the number of oocytes with GV,
GVB and polar bodies (hereinafter designated PB), respectively, were counted using a stereo microscope (Wildt, Leica MZ 12). The percentage of GVB, defined as per- centage of oocytes undergoing GVB per total number of oocytes in that well, was calculated as: % GVB = (number of GVB + number of PB)/ total number of oocytes) X 100.
Example 2
Procedure
All IVF patients can potentially receive this treatment, age range 20 to 45 year. The hormonal treatment can be a short or long gonadotropin based treatment with or without pituitary down regulation or with and without the use of GNRH antagonist and with or without the use of hCG. Future appropriate hormonal therapies designed for
IVF can also be used. Medium to full size follicles (size 10 to 25 mm, preferential 16 to 20 mm follicles) will be aspirated under ultrasound guidance.
SUBSTITUTE SHEET (RULE 26)
w » 11 - . The aspirated fluid will be searched for cumulus oocytes complexes (COC) and once identified under the stereomicroscope (with or without the use of embryo filters), the COC will be placed in culture.
The exposure to FF-MAS can vary from 1 to 60 hours, preferentially from 4 to 30 hours, and can be before, under and up to 24 hours after fertilisation. A wide variety of oocyte culture media or media components known to the skilled worker can be used. Human serum albumin (HSA) may or may not be added to the medium. if added, it can be in a concentration of 0.1 to 100 mg/m, preferentially 5 to 15 mg/ml or 0.5 to 1.5 % volume/volume. The formulation of FF-MAS may be in the form of an ethanol stock solution, DMSO or other organic solvent solution or it may be in form of
FF-MAS/HSA dry coated wells ready to use just by adding the appropriate culture medium. The concentration of FF-MAS may vary from 0.1 uM to 100 uM, preferen- tially 10 to 30 pM.
Following or during in vitro culture with FF-MAS, the oocytes may be fertil- ised by conventional IVF or by intracytoplasmatic sperm injection (ICSI) or by future appropriate fertilisation methods leading to fertilised zygotes. The developing embryo may be transferred on day 1 to day 6 after fertilisation, preferentially on day 2 to 3, either as single egg transfer or multiple egg transfer.
The patient can receive progesterone and/or oestrogen therapy before and : 20 after the egg transfer in individually designed protocols to prime and sustain appro- priate receptive endometrial lineage.
Compared with the know procedures, better results were obtained using the above procedure.
Example 3
Use of FF-MAS as adjunct to a standard FSH based IVF treatment
The patient underwent down regulation with recombinant FSH with an aver- age daily dose of 225 IU starting on Day 1 or 2 of the current cycle and used a GnRH antagonist, i.e., Cetrorelix (1 mg daily, subcutaneously, one shot), in the current cy- cle. At least 3 follicles of 17 mm or more were present at the time of administering hCG, i.e., Profasi (10.000 IU, one shot). Follicles were aspirated and metaphase
SUBSTITUTE SHEET (RULE 26)
oocytes were cultured in oocyte culture system containing standard in vitro fertiliza- tion (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB,
Gothenburg, Sweden)) supplemented with human serum albumin (0.8%) and FF-
MAS (5 pM). All oocytes were cultured under normal conditions at 37°C in the incu- bator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours (+30 minutes) before intracytoplasmic sperm injection (hereinafter desig- nated ICSI) and 20 hours (+1 hour) after ICSI in the above IVF 20 medium. Preem- bryos were evaluated for cleavage stage and fragmentation / morphology at 1, 2 and 3 days post ICSI. After 3 days of culture, a selection of the best preembryos, typically two preembryos, was replaced to the female patient. The female patient received an estrogen, i.e., Estrofem (6 mg/daity), and a progesterone, i.e. Utrogestan (600 mg/daily, micronized, vaginal suppository), to render the endometrium lining the pa- tient uterus responsive and ready for allowing implantation of the transferred eggs.
The continuation of supporting steroid hormones was patient depending and was seponated after 3-10 weeks depending on ultrasound scans and blood testing.
Compared with the know procedures, better results were obtained using the above procedure.
Example 4
Use of FF-MAS as adjunct to a standard FSH based IVF treatment
The patient underwent down regulation with an GnRH analog, i.e., Synarel (nasal spray, two puffs daily), for at least 14 days (starting in the luteal phase of the previ- ous cycle or Day 1 or 2 in the follicular phase of the current cycle) and ovarian stimu- lation with recombinant FSH with an average daily dose of 225 IU. At least 3 follicles of 17 mm or more were present at the time of administering hCG, i.e. Profase (10.000 IU, one shot). Follicles were aspirated and metaphase Il oocytes were cul- tured in oocyte culture system containing standard in vitro fertilization (IVF) media (IVF 20 (which is available from Scandinavian IVF Science AB, Gothenburg, Swe-
SUBSTITUTE SHEET (RULE 26)
: den)) supplemented with human serum albumin (0.8%) and FF-MAS (5 uM). All oo- cytes were cultured under normal conditions at 37°C in the incubator. Each oocyte was cultured in one well in a four-chamber culture dish as culture media system. The duration of exposure to the culture media with treatment was 4 hours (x30 minutes) before intracytoplasmic sperm injection (ICSI) and 20 hours (+1 hour) after ICSI in the above IVF 20 medium. Preembryos were evaluated for cleavage stage and fragmentation / morphology at 1, 2 and 3 days post ICSI. After 3 days of culture, a selection of the best preembryos, typically two preembryos, was replaced to the fe- male patient. The female patient received an estrogen, i.e., Estrofem (6 mg/daily), and a progesterone, i.e., Utrogestan (600 mg/daily, micronized, vaginal suppository), daily to render the endometrium lining the patient uterus responsive and ready for allowing implantation of the transferred eggs. The continuation of supporting steroid hormones was patient depending and was seponated after 3-10 weeks depending on ultrasound scans and blood testing.
Compared with the know procedures, better results were obtained using the above procedure.
Example 5
Using the procedure described in Example 3 with the proviso that in stead of using
FF-MAS in a concentration of 5 uM, FF-MAS was used in a concentration of 20 uM, better results were obtained than with the know procedures.
Example 6
Using the procedure described in Example 4 with the proviso that in stead of using
FF-MAS in a concentration of 5 pM, FF-MAS was used in a concentration of 20 pM, better results were obtained than with the know procedures.
SUBSTITUTE SHEET (RULE 26)
Claims (15)
1. A method for human in vitro fertilisation wherein a woman, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof where after oocytes are aspirated and actively matured or synchronised in vitro in con- tact with a MAS compound.
2. The use of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof in the manufacture of a hor- mone product which is to be administered to a woman who, within a consecutive period of 30 days, is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof, and from whom, immediately after said period, one or more oocytes are aspirated, where after said oocyte(s) is/are cultivated in a convenient medium containing a MAS compound as defined herein, where after said oocyte(s) is/are fertilised with human sperm, and where after the resulting embryo(s) is/are transferred to a woman,
3. Use of a hypothalamic hormone and/or a pituitary hormone or an agonist or an- tagonist thereof or an active derivative thereof and of a MAS compound for the manufacture of a medicament for the treatment of human in vitro fertilisation wherein a hypothalamic hormone and/or a pituitary hormone or an agonist or an- tagonist thereof or an active derivative thereof is, within a consecutive period of days, used to treat a women and, thereafter, the MAS compound is used in an in vitro oocyte maturation of the egg or eggs retrieved from this woman.
4. A method or use according to any one of the preceding claims wherein the woman is treated for infertility, and/or for improving the maturation of her oo- 30 cytes, and/or for improving the synchrony of nuclear, cytoplasmic and/or mem- branous oocyte maturation, and/or for improving the fertility of her oocytes, SUBSTITUTE SHEET (RULE 26)
and/or for improving the rate of implantation by human in vitro maturation and fertilisation
5. A method or use according to any one of the preceding claims wherein the con- secutive period of 30 days within which the woman is treated with a hypotha- lamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof is at least about 7 days, preferably at least about 10 days, more preferred at least about 14 days.
6. A method or use according to any one of the preceding claims wherein the con- secutive period is one menstrual cycle.
7. A method or use according to the previous claim wherein the maturation of the oocytes with the MAS compound is for a duration of about 15 to about 60 hours.
8. A method or use according to any one of the preceding claims wherein preovula- tory follicles are induced to lutenise with a luteinising hormone (LH) or an agonist : or antagonist thereof or an active derivative thereof and/or human chorion go- nadotropin (HCG) or an agonist or antagonist thereof or an active derivative thereof.
8. A method or use according to the previous claim wherein the maturation of the oocytes with the MAS compound is for a duration of about 1 to about 15 hours, preferably about 6 hours.
10. A method or use according to any one of the previous claims wherein the dosage of MAS compound is about 0.01 to about 100 nmol per litre, preferably about
0.1 to about 100 umol per litre.
11. A method or use according to any one of the previous claims, wherein the MAS compound is one of the compounds mentioned in WO 96/00235, 96/27658, SUBSTITUTE SHEET (RULE 26)
97/00884, 98/28323, 98/54965 and 98/55498, more specifically compounds mentioned in Claim 1 thereof.
12. A method or use according to the previous claim wherein the MAS compound is FF-MAS.
13. A pharmaceutically kit in unit dosage form for use by in vitro fertilisation compris- ing separate unit dosages, said kit comprising separate dosage units for sequen- tial daily administration of a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for sequential daily administration and 1 dosage units of a MAS compound.
14. A kit according to the previous claim having the preferred features described in any one of the above subclaims.
15. Any novel feature or combination of features described herein. SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900255 | 1999-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200104803B true ZA200104803B (en) | 2002-02-13 |
Family
ID=8091487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200104803A ZA200104803B (en) | 1999-02-24 | 2001-06-13 | Treatment of infertility. |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL350221A1 (en) |
| ZA (1) | ZA200104803B (en) |
-
2000
- 2000-02-23 PL PL00350221A patent/PL350221A1/en not_active Application Discontinuation
-
2001
- 2001-06-13 ZA ZA200104803A patent/ZA200104803B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL350221A1 (en) | 2002-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6281013B1 (en) | Treatment of Infertility | |
| US6585982B1 (en) | Treatment of infertility | |
| US5869081A (en) | Progesterone vaginal ring for treatment of infertility | |
| EP1578427B1 (en) | Use of gnrh agonists to support the luteal phase during infertility treatment | |
| Zhang et al. | Effects of follicle‐stimulating hormone and ovarian steroids during vitro meiotic maturation on fertilization of rat oocytes | |
| RU2221588C2 (en) | Method for therapeutic treatment of sterility | |
| Crawford et al. | The hypothalamic–pituitary–ovarian axis and manipulations of the oestrous cycle in the brushtail possum | |
| Fauser | Follicular development and oocyte maturation in hypogonadotrophic women employing recombinant follicle-stimulating hormone: the role of oestradiol | |
| JP2005530818A (en) | Ovarian hyperstimulation control method and pharmaceutical kit used in the method | |
| EP1235899B1 (en) | Treatment of human infertility | |
| ZA200104803B (en) | Treatment of infertility. | |
| CA2362940A1 (en) | Treatment of infertility | |
| Rizk et al. | Clinical infertility and in vitro fertilization | |
| Serhal | Oocyte donation and surrogacy | |
| ZA200104653B (en) | Treatment of infertility. | |
| Abu-Musa et al. | Artificial endometrial preparation for oocyte donation using synthetic estrogen and progestogen | |
| Feinberg et al. | The evolution of in vitro fertilization: integration of pharmacology, technology, and clinical care | |
| MXPA01008452A (en) | Treatment of infertility | |
| Buckett et al. | In vitro maturation of oocytes | |
| Dhanda et al. | Ovarian hormones and their role in oestrous cycle in animals: A review | |
| Serhal | Oocyte donation | |
| GREENWALD | GILBERT S. GREENWALD |